NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets decreased their price target on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Stock Up 2.0 %

NYSE NBY opened at $0.60 on Friday. NovaBay Pharmaceuticals has a 52 week low of $0.36 and a 52 week high of $9.08. The business has a 50 day moving average price of $0.66 and a 200-day moving average price of $0.62. The company has a market cap of $2.93 million, a price-to-earnings ratio of -0.01 and a beta of 0.73.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.